Numerous studies have explored a correlation between obesity and brain health. The research suggests a connection between excess body fat and cognitive issues, including reduced executive function skills, limited brain plasticity, and higher dementia risk. Here’s the trouble: Scientists still don’t know how, exactly, obesity leads to cognitive decline. New research published in Radiology explores how obesity affects the brain, honing in on a surprising factor: the location of fat in the body, not just the amount.
Sneaky Fat and Cognitive Decline: An Invisible Ripple Effect
Experts are aware that obesity can contribute to cognitive decline. Unfortunately, the precise mechanics of that impact remain unclear. To explore the connection, researchers from the Affiliated Hospital of Xuzhou Medical University in Xuzhou, China, explored how specific fat storage patterns relate to cognitive risk, designing a study around the assertion that “adiposity reduces brain gray matter volume, increases white matter lesion burden, and disrupts neural circuitry.”
Using MRI Imaging to Pinpoint Fat Distribution
The study points to “increasing evidence” that the impact of obesity “varies considerably according to the anatomic location of fat depots.” For example, fat accumulation in the pancreas may be correlated with different cognitive changes than, say, fat accumulation in the heart.
Of course, internal fat distribution is impossible to gauge without medical imaging. Thus, to evaluate these connections, the researchers used imaging and health data from 25,997 participants pulled from the UK Biobank. The team relied on anonymized MRI scans, which enable more “precise quantification of adipose tissue” — a closer look at where fat deposits are distributed — than simple x-ray imaging. By linking the MRI scans with other data, including disease markers, medical history, and lifestyle factors, the team was able to evaluate brain health outcomes based on fat distribution profiles.
The Hidden Dangers of “Skinny Fat”
The team ultimately identified six profiles of body fat distribution in both sexes. Among the patterns identified, two appeared to be correlated with the most significant cognitive decline: the “pancreatic-predominant” and the “skinny fat” profiles. Both were strongly associated with cognitive changes, including gray matter loss and faster brain aging in both sexes.
As the name suggests, people with the “pancreatic-predominant” pattern showed a higher level of fat concentration in pancreatic tissue. The “skinny fat” profile is a bit more surprising. In a press release, study coauthor Kai Liu explained that the “skinny fat” individual “does not fit the traditional image of a very obese person, as its actual average BMI ranks only fourth among all categories.” Individuals in this category tend to have a higher overall fat quantity despite not appearing severely obese. In other words: It’s impossible to gauge someone’s precise fat distribution type by evaluating their appearance. To assess fat distribution risk and its potential impact on cognition, researchers need to look deeper.
_____
This research could provide healthcare providers with a more effective framework for protecting brain health. It may also encourage providers to think beyond traditional measures of health, such as body mass index (BMI). Per study coauthor Kai Liu, “Brain health is not just a matter of how much fat you have, but also where it goes.” Further research is needed to understand how fat distribution patterns may influence brain health and other health outcomes.
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.